Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

595 trials

NCT07169500
Recruiting
Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
Phase 1/2 · China · 1 site
Registry update: 2 Mar 2026
NCT06644625
Recruiting
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
Not applicable · United States · 1 site
Registry update: 13 Jul 2026
NCT06879379
Recruiting
KPD Consolidation After ASCT in NDMM Patients
Phase 2/3 · China · 3 sites
Registry update: 17 Mar 2025
NCT06971380
Recruiting
Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis
Phase 2 · Israel · 1 site
Registry update: 4 Nov 2026
NCT07642362
Recruiting
Digital Support for Multiple Myeloma Quality of Life
Not applicable · Greece · 1 site
Registry update: 11 Jun 2026
NCT06789003
Recruiting
Evaluation of a PREHABilitation Protocol Using Adapted Physical Activity (APA) for Multiple Myeloma Patients Eligible for Intensive Autologous Stem Cell Transplantation Treatment
Not applicable · France · 1 site
Registry update: 3 Mar 2026
NCT06793449
Recruiting
BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
Phase 2 · China · 1 site
Registry update: 3 Aug 2025
NCT05745285
Recruiting
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
Not applicable · United States · 3 sites
Registry update: 16 Oct 2026
NCT06821880
Recruiting
Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project
Not applicable · Austria, Germany · 5 sites
Registry update: 12 Feb 2025
NCT07477912
Recruiting
Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma
Phase 1/2 · Belarus · 1 site
Registry update: 16 Oct 2026
NCT06799026
Recruiting
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
Phase 1 · United States · 2 sites
Registry update: 7 May 2026
NCT06015542
Recruiting
Self-administration of Subcutaneous Elranatamab in the Patients' Homes.
Phase 2 · Denmark · 2 sites
Registry update: 10 Feb 2026
NCT06791681
Recruiting
A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma
Early phase 1 · China · 1 site
Registry update: 11 Feb 2025
NCT07577206
Recruiting
Single Microdose Trial- CXCR4 PET Tracer - Pharmacokinetics and Pharmacodynamics of [68Ga]Ga-R54, a Radiopharmaceutical Directed Toward CXCR4 in Patients With Advanced Solid Neoplasia.
Early phase 1 · Italy · 1 site
Registry update: 11 May 2026
NCT06846905
Recruiting
Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.
Not applicable · France · 1 site
Registry update: 26 Feb 2025
NCT06855121
Recruiting
The Norwegian Immunotherapy in Multiple Myeloma Study
Not applicable · Norway · 23 sites
Registry update: 20 Jul 2026
NCT06758713
Recruiting
Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
Phase 1 · China · 1 site
Registry update: 6 Jan 2025
NCT06759181
Recruiting
Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
Phase 1/2 · China · 1 site
Registry update: 6 Jan 2025
NCT06745687
Recruiting
BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma
Not applicable · China · 1 site
Registry update: 23 Jul 2026
NCT06690593
Recruiting
Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy
Not applicable · China · 1 site
Registry update: 27 Dec 2024

Ordered by registry start date. Freshness and sponsorship never change the order.